Trial to Assess Chelation Therapy (TACT2)

Book Your AppointmentGet Directions

Trial to Assess Chelation Therapy (TACT2)

Diabetes? Heart attack? Over 50?

Are you a diabetic, over 50, who has suffered a heart attack? You may be eligible to participate in a study to assess the impact of chelation therapy, to reduce your future risk of heart attack, stroke or sudden death. To find out more about the FREE, nationwide study, contact us at 856-424-8222.

EXCELLENT (AND UNEXPECTED) RESULTS! 

When analyzing the results of the first Trial to Assess Chelation Therapy (TACT), researchers found that a subgroup of patients with diabetes who received EDTA chelation had fewer cardiovascular events than patients who did not receive EDTA chelation. This was not what researchers were expecting to find.

Remarkably, there was a 43% reduction in mortality and a 51% reduction in overall cardiac events which included heart attack, stroke or sudden death in the diabetics who were treated with chelation therapy. This was quite dramatic! It should also be noted that in the original TACT study, in which there were more than 1700 patients and 55,000 treatments given, chelation therapy was found to be safe.

TACT2 is the second Trial to Assess Chelation Therapy.

What is Chelation Therapy?

Chelation therapy is a research medicine given through an IV. Some scientists believe that chelation therapy may help to treat heart disease by removing toxins from the blood. However, this has not yet been proven. This study will find out if chelation works in treating heart disease in patient with diabetes.

What will the study involve?

If you join the study, you will be assigned to receive either active IV drug OR IV placebo (inactive study drug).

The IV is administered weekly for approximately 40 weeks. Each IV session lasts approximately three to four hours. In addition, you will take either high-dose oral vitamin and mineral supplements or identical placebo pills. All participants will receive low-dose vitamin and mineral supplements during the time they are receiving IV treatment. You will continue to take your standard diabetes and heart disease medications.

What are the costs?

The study drugs will be provided at no cost. Other medical costs remain your responsibility.

Why is TACT2 important?

If TACT2 finds the same results as TACT1, EDTA chelation therapy may become a novel guideline-supported therapeutic option for patients with coronary artery disease who are already on evidence-based medical therapy.

Interested in participating? Complete the form belowGET IN TOUCH WITH US!